GMED vs IDXX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

GMED

41.1
AI Score
VS
GMED Wins

IDXX

31.7
AI Score

Investment Advisor Scores

GMED

41score
Recommendation
HOLD

IDXX

32score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric GMED IDXX Winner
Forward P/E 14.2653 41.6667 GMED
PEG Ratio 1.7253 3.2827 GMED
Revenue Growth -0.7% 9.9% IDXX
Earnings Growth 18.2% 17.9% GMED
Tradestie Score 41.1/100 31.7/100 GMED
Profit Margin 17.8% 25.4% IDXX
Beta 1.00 1.00 Tie
AI Recommendation HOLD EXTENDED Tie

Relative Price Performance (Last 90 Days)

GMED 1M: -4.1% · 3M: -14.8% IDXX 1M: +32.9% · 3M: +27.6%

Current Technical Phase

GMED

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.7%), weak momentum, RSI 43

RSI (14): 43.0 · Price: $73.17

IDXX

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (4.3% over 20 days), RSI 72

RSI (14): 72.2 · Price: $702.81

Fundamentals Snapshot

Metric GMED IDXX
Market Cap — —
Forward P/E 14.1 41.6
Trailing P/E 18.5 46.9
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.7% 0.6%
Operating Margin 0.2% 0.3%
EPS 4.06 14.84
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GMED is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.